Keratin 15 (K15) is a type I keratin without a defined type II partner whose expression in epidermal diseases has not been investigated. In this study we have used LHK15, a monoclonal antibody raised against the last 17 amino acids of the K15 polypeptide, to show that K15 is expressed primarily in the basal keratinocytes of stratified tissues, including the fetal epidermis and fetal nail. Although K15 in normal hair follicles was virtually absent from hair bulbs, it was expressed by a subset of keratinocytes in the outer root sheath. By comparison, K14 expression was found throughout the outer root sheath of hair follicles; however, when both K14 alleles were naturally ablated, the expression of K15 was also observed throughout the outer root sheath of the follicles. Expression of K15 mRNA was assessed by in situ hybridization and corroborated the data from immunostaining. An increase in K15 mRNA and protein expression in hair follicles from the K14 ablated epidermis suggested an upregulation of the K15 gene in the absence of the K14 protein. In organotypical cultures where differentiating keratinocytes expressed markers of activated phenotype, i.e., K6 and K16, expression of K15 was undetectable. The expression of K15 mRNA and protein was also downregulated in two hyperproliferating situations, psoriasis and hypertrophic scars. Because keratinocytes in psoriasis and hypertrophic scars are activated, we conclude that K15 expression is not compatible with keratinocyte activation and the K15 gene is downregulated to maintain the activated phenotype.

BackgroundPlatelet-rich plasma (PRP) is an autologous concentration of human platelets contained in a small volume of plasma and has recently been shown to accelerate rejuvenate aging skin by various growth factors and cell adhesion molecules.ObjectiveThis study was conducted to evaluate the efficacy and safety of intradermal injection of PRP in the human facial rejuvenation.MethodsThis study was a prospective, single-center, single-dose, open-label, non-randomized controlled clinical study. PRP injected to the upper site of this right infra-auricular area and all face. Saline was injected to the left infra-auricular area. Histopathological examinations were performed before PRP treatment, 28 days after the PRP, and saline (control) treatments.ResultsTwenty women ranging in age from 40 to 49 years (mean age, 43.65±2.43 years) were enrolled in the study. The mean optical densities (MODs) of collagen in the pre-treatment, control, and PRP-treated area were measured. They were 539±93.2, 787±134.15, 1,019±178, respectively. In the MOD of PRP, 89.05 percent improvement was found when MOD of PRP was compared with MOD of pre-treatment. The mean MOD of collagen fibers was clearly highest on the PRP side (p<0.001). The PRP-to-saline improvement ratio (89.05% to 46.01%) was 1.93:1. No serious side effects were detected.ConclusionPRP increases dermal collagen levels not only by growth factors, but also by skin needling (the mesotherapy technique 'point by point'). PRP application could be considered as an effective (even a single application) and safety procedure for facial skin rejuvenation.

COVID-19 pandemic has a significant impact on public health, whether directly or indirectly. The first case was seen in Turkey on March 11, and the World Health Organization (WHO) declared a pandemic on March 12, 2020. The study aimed to document the effect of pandemic on dermatology outpatient clinics in Turkey. Fifteen tertiary hospitals from 13 provinces were included in the study, which was conducted between January 12 and May 12, 2020. The International Codes of Diseases (ICD-10) categories and patients' characteristics were evaluated before and after the pandemic. A total of 164 878 patients, 133 131 before and 31 747 after the pandemic, were evaluated. The daily hospital applications were found reduced by 77%. The three of the most frequent diagnoses; dermatitis, acne, and psoriasis remained unchanged after the pandemic. While the frequency of herpes zoster, scabies,

Background: Alopecia areata (AA) and vitiligo are associated with various psychiatric comorbidities, and the care of a child with AA or vitiligo may be associated with higher anxiety and depression than healthy children. Aims:We aimed to identify psychiatric findings in children and adolescent groups with AA and vitiligo and to evaluate the levels of anxiety and depression in their parents.Methods: This study included 31 patients with AA and 29 patients with vitiligo, aged seven to 17 years, and their parents. Age-and gender-matched 30 controls and their parents were included. The patients and controls completed the Revised Child Anxiety and Depression Scales-Child version (RCADS-C), and their parents completed the parent version (RCADS-P). The parents also completed the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI). In addition, the stressful event history of all cases was noted.Results: Stressful event history was higher in the vitiligo group compared to the AA group, and it was higher in the AA and vitiligo groups compared to the control group. Separation anxiety, generalized anxiety, social phobia, and major depressive disorder (MDD) scores were higher in the AA group than controls according to the RCADS-C. According to the RCADS-P, panic disorder (PD), MDD, and total anxiety scores were higher in the AA group. Only the PD and MDD scores were higher in the vitiligo group than those of the controls based on the RCADS-P. Lastly, no significant difference was observed between the three groups concerning the parents' BAI and BDI scores.Conclusions: Stressful events were more common in pediatric patients with vitiligo than those with AA. Anxiety symptoms were more prevalent in patients with AA than those with vitiligo. K E Y W O R D S alopecia, psychological aspects, quality of life, vitiligo | 2233 Savaş ERDOĞaN Et al.How to cite this article: Erdoğan SS, Gür TF, Doğan B. Anxiety and depression in pediatric patients with vitiligo and alopecia areata and their parents: A cross-sectional controlled study. J

The experimental programme of the EC supported project (SMT 2070) SOTA aimed at addressing a technical and industrial need to provide guidelines for creep crack growth (CCG) testing and data analysis of weldments. Mechanical and creep properties were determined on two pressure vessel steels of P22 (2.25Cr1Mo) and P91 (9Cr1MoVNb). The specimens were taken from pipe welds for weld metal (WM) tests, and simulated heat affected zone (HAZ) material for the HAZ tests. Creep crack growth (CCG) tests were carried out on cross-weld compact tension (CT) specimens machined out from weldment of pipes. The tests were done at 550 °C and 600 °C on P22 and P91 materials, respectively. The CT specimens were notched using electrical discharge method (EDM), for a sharp starter crack. This method of initiating sharp starter crack was chosen to make sure that all partners will test specimens with starter crack location as specified in the work programme to study crack initiation and growth in WM, HAZ (both in the centre and type IV region). The CCG tests were carried out following the ASTM E1457-92 [Ref.1]. The partners assessed their data and sent both assessed and their raw data to be further assessed centrally. All the data from partners were analysed and compared with those of partners' own assessed data. The present paper reports on the analyses of CCG data obtained in the programme including six laboratories from six European countries. The programme addresses the differences and difficulties in testing and the assessment of weldments, and provides guidelines for harmonisation of testing procedures for reliable data production for remanent life assessment of plants with welded components.